Objective. CD200/CD200R1 signalling has an immunoregulatory effect on the activation threshold of the inflammatory immune response and maintains immune homeostasis. In this study we evaluated the status of CD200/CD200R1 interaction in patients with RA.
Introduction
RA is a chronic inflammatory autoimmune disease characterized by persistent synovitis and progressive bone erosion. Current treatments, such as TNF-a inhibitor therapy, have focused on alleviating synovitis but do not adequately repair bone and cartilage erosion, thereby warranting the development of new treatments that not only inhibit inflammatory synovitis but also effectively stop or reverse bone and cartilage destruction.
CD200 is a type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily and is expressed on a variety of cells, including myeloid-derived cells, activated T cells, B cells and neurons [1, 2] . CD200 consists of an extracellular, a transmembrane and an intracellular domain. Its intracellular region lacks a signalling motif, therefore signalling from CD200 can be transduced via its receptors [3] , including CD200R14, of which CD200R1 has the highest binding affinity [46] . As CD200 receptors are present mainly on myeloid-derived cells, such as dendritic cells, macrophages and activated T cells [7] , the known immunoregulatory roles of the CD200/CD200R1 pathway are focused on the suppression of myeloid-derived cell activation, including negative regulation of macrophage function and repression of the degranulation of mast cells and basophils [811] . Moreover, Gorczynski et al. [12] found that CD200-deficient mice had increased susceptibility to developing CIA. Administration of CD200R-Ig to disrupt the CD200CD200R interaction was also found to increase the susceptibility of mice to CIA [13] . Simelyte et al. [14] reported that CD200Fc can be an effective therapeutic agent for established CIA owing to its targeting of proinflammatory cytokine expression in the joint. The authors confirmed that the CD200/CD200R1 pathway in CIA plays a significant physiological role in regulating disease severity [15] . Although the available evidence has highlighted an important role for CD200/CD200R in experimental autoimmune diseases, the role of CD200/CD200R1 in human autoimmune diseases, such as RA, remains unknown. Previously we reported that aberrant CD200/CD200R1 expression and function in SLE contributes to abnormal T cell responsiveness and dendritic cell activity [16] . In this study we explored the expression and function of this pathway in subjects with RA.
Materials and methods

Patients and healthy controls
This study was approved by the Institutional Review Board of Peking Union Medical College Hospital and written informed consent was obtained from each participating patient and healthy control (HC). Altogether, a total of 30 RA patients with active disease and fulfilling the 1987 ACR revised criteria for RA were enrolled in the study (3 men and 27 women), ranging in age from 43 to 67 years. Mean disease duration at the time of evaluation was 8.8 years and none had received non-biologic or biologic DMARDs before entering this study. Clinical disease activity was determined using the 28-joint DAS with CRP (DAS28-CRP).
Thirteen patients were treated with infliximab (anti-TNFa monoclonal antibody) plus MTX and underwent two MRI assessments. The first was performed at the time of starting treatment and the second at week 30 (after five infusions of infliximab). The MRI images were scored for synovitis and bone oedema by two independent, blinded readers using the OMERACT Rheumatoid Arthritis MRI Scoring System (RAMRIS) [17] . Bone oedema was scored as 03 using the following criteria based on the volume of oedema: 0, no oedema; 1, 133% bone oedema; 2, 3466% bone oedema; 3, 67100% bone oedema. Synovitis was scored as 03 based on the volume of contrast-enhanced tissue in the synovium compartment in three wrist regions (A, the distal radioulnar joint; B, the radiocarpal joint; C, the intercarpal and carpometacarpophalangeal joints) and each MCP joint (0: normal; 1: mild; 2: moderate; 3: severe). Five genderand age-matched patients with OA and 10 gender-and age-matched healthy volunteers were enrolled as patient controls and HCs.
Antibodies and reagents
Monoclonal antibodies targeting the following molecules were used, either unlabelled or as FITC, phycoerythrin (PE), allophycocyanin (APC) or PE-cyanin7 (PE-Cy7) conjugates: CD4 (RPA-T4), CD14 (61D3), IFN-g (B27), Foxp3 (PCH101), CD200R (OX-108), CD80 (L307.4), CD25 (BC96), CD200 (OX104), CCR6 (R6H1), CD86 (IT2-2), CD3 (UCHT1), CD28 (CD28.2) and CD200R (OX-108) (BD Pharmingen, San Diego, CA, USA); IL-17 (64DEC17) (eBioscience, San Diego, CA, USA); CD80 (L307.4) and CD86 (IT2-2) (BioLegend, San Diego, CA, USA). In all of the experiments, control mAbs for the respective IgG isotypes were included. The Cell Trace carboxyfluorescein succinimidyl ester (CFSE) cell proliferation kit and the Apoptosis Assay kit #2 were obtained from Invitrogen (Carlsbad, CA, USA). Recombinant IL-2, IL-4, IL-6, IL-1b, IL-23, TGF-b and CCL20 were all purchased from PeproTech (Rocky Hill, NJ, USA). Lipopolysaccharide (LPS), ionomycin and phorbol 12-myristate 13-acetate (PMA) were obtained from Sigma-Aldrich (St Louis, MO, USA). Additionally, tartrate-resistant acid phosphatase (TRAP) expression was measured using a commercial kit obtained from Sigma-Aldrich. Recombinant human CD200Fc, M-CSF, receptor activator for nuclear factor kB ligand (RANKL), anti-mouse CD200 antibody (goat IgG) and anti-human CD200 R1 antibody (goat IgG) were purchased from R&D Systems (Minneapolis, MN, USA). Antibodies against DOK2 (ab47507) and phosphorylated DOK2 (pDOK2; phospho Y299) were purchased from Abcam (Cambridge, UK). used to set up the threshold of positivity for each marker.
Immunohistochemistry
Synovial tissue was collected with arthroscopy. The samples were collected from five untreated active RA patients, five patients with OA and five HCs after obtaining informed consent from each patient and control. Immunohistochemistry was performed using an immunoperoxidase technique with diaminobenzidine to examine the expression of CD200 and CD200R1 in synovium from HCs and OA and RA patients. The specificity of staining was confirmed by using matched-isotype control antibodies. Stained sections were evaluated semi-quantitatively using scoring systems for synovial tissue. All areas of specimens were analysed and a histological score was calculated. A score of 0 represented the lowest and 3 the highest level of CD200/CD200R1 expression [18] . Finally, the slides were photographed using a transmitted light microscope (Eclipse 80i; Nikon, Tokyo, Japan).
Western blotting CD4 + T cells were cultured with recombinant human
CD200Fc at a dosage of 200 ng/ml. The IgGFc isotype at the same dosage was used as control. After 5 days the cells were harvested, washed twice in ice-cold PBS and lysed by incubation for 1 h in a buffer containing 20 mM N-2-hydroxyethylpiperazine-N-2-ethanesulphonic acid (HEPES; pH 7.9), 20% glycerol, 1% Nonidet P-40, 1 mM MgCl 2 , 0.5 mM EDTA, 0.1 mM ethylene glycol tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulphonyl fluoride (PMSF) and a proteinase inhibitor cocktail (BD Biosciences, Franklin Lakes, NJ). The lysates were kept on ice and vortexed every 10 min for 1 h before centrifugation at 12 000g at 4 C. Equal amounts of protein were separated by SDS-PAGE (Invitrogen), transferred to Immobilon polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA), blocked with 5% dried milk in PBS containing 0.5% Tween 20, incubated with specific antibodies against DOK2 or pDOK2, then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody and finally developed using Western Lightning Chemiluminescence Reagent Plus (PerkinElmer Life Sciences, Boston, MA, USA).
Transwell migration assay
The induced human Th17 cells were seeded in the upper chambers of the transwell. The lower chambers were filled with CCL20 alone or in the presence of the IgGFc isotype or CD200Fc. After 8 h of incubation, the cells that migrated to the lower chamber were counted.
Generation of monocyte-derived osteoclast and TRAP + staining CD14 + monocytes (1 Â 10 6 cells/ml) were cultured with M-CSF (30 ng/ml) and RANKL (100 ng/ml) alone or in the presence of the IgGFc isotype or CD200Fc for 14 days.
In vitro osteoclast differentiation was analysed by TRAP + staining according to the manufacturer's protocol.
Statistical analysis
All data were analysed using SPSS 13.0 software (SPSS, Chicago, IL, USA). The data that passed the KolmogorovSmirnov and ShapiroWilk tests (P > 0.05) were considered to be a normal distribution. For the data with a normal distribution and homogeneity of variance [mean (S.E.M.)], one-way analysis of variance with adjusted Bonferroni correction was used to assess the differences between the groups. An independent-sample t-test and paired-sample t-test were used to compare the differences between two groups and the differences before and after treatment. For data with a non-normal distribution [median (25th75th percentiles)], the MannWhitney test was used to compare differences between two groups. Correlations between ÁDAS28, ÁMRI, ÁTh1, ÁTh17 and ÁTreg (CD4 + CD25 + Foxp3 + T cell) with changes in CD200 and CD200R1 were calculated using Spearman's rho test. P-values <0.05 were considered statistically significant.
Results
Aberrant expression of CD200/CD200R1 in human RA First we examined the expression of CD200 and CD200R1 by various cell subtypes in patients with active RA and found that the proportion of CD200 + cells in the PBMCs, Stained sections were evaluated semi-quantitatively using scoring systems for synovial tissue. All areas of specimens were analysed and a histological score was calculated. A score of 0 represented the lowest and 3 the highest level of CD200/ CD200R1 expression. 
CD200 expression in synovium
We next examined CD200/CD200R1 expression in synovium of RA patients and compared it with that of HCs and OA patients. We found that in contrast to CD200 + cells in OA synovium, which were mainly identified in the lining layer and to a lesser extent in the sublining layer, CD200 + cells in RA synovium also extended into the deeper layer. Table S1 , available at Rheumatology Online).
CD200Fc effects on CD4 + T cell proliferation, necrosis and apoptosis
We confirmed that soluble CD200Fc could trigger CD200/ CD200R1 signalling by inducing the phosphorylation of DOK2 in CD4 + T cells from RA patients (Fig. 2A) . 
CD200Fc effects on Th17 differentiation and chemotactic CCR6 expression
Then we examined whether CD200Fc could affect CD4 + T cell differentiation into Th17 cells and found that TGF-b, IL-1b, IL-23 and IL-6 in vitro induced Th17 cell differentiation in active RA patients and HCs, which was inhibited by in vitro CD200Fc (Fig. 3A) . Interestingly, Th17 cell differentiation was also reduced in CD4 + T cells from RA patients after treatment with DMARDs that increased cell expression of CD200/CD200R1 (Fig. 3B ). In addition, we also generated Th17 cells by co-incubation of CD4 + T cells from RA patients (HCs as control) with peripheral or synovial CD14 + cells isolated from the same RA patients and found that both peripheral and synovial CD14 + cells from RA patients increased the generation of Th17 cells and this Th17 generation was significantly inhibited by in vitro CD200 Fc (Fig. 3C) . As CCR6 is a critical chemokine involved in Th17 migration to the inflammatory site in RA, we then examined whether CD200Fc could also affect CCR6-mediated Th17 chemotaxis and found that CD200Fc down-regulated CCR6 expression by Th17 cells and inhibited CCL20-mediated Th17 chemotaxis in RA patients, as assessed by transwell experiments (Fig. 3D ).
CD200Fc inhibition of peripheral CD14 + monocyte-derived osteoclast generation
Given that abnormal CD200/CD200R1 expression by CD4 + T cells was corrected after treatment with infliximab plus MTX in RA patients, correlating with less radiographic progression, we explored whether CD200Fc can regulate osteoclast generation in RA patients. We generated osteoclasts by stimulating peripheral blood CD14 + monocytes from RA patients with M-CSF and RANKL and found that in vitro CD200Fc reduced osteoclastogenesis as demonstrated by TRAP staining (Fig. 4A) . When we stimulated RA peripheral CD14 + cells with LPS, the expression of CD80 and CD86 was up-regulated, and this up-regulation was inhibited by in vitro CD200Fc in RA patients but not HCs (Fig. 4B ).
Discussion
Recent studies have shown that the CD200/CD200R1 pathway has an immunosuppressive effect on the inflammatory cellular immune response and participates in the modulation of the severity of autoimmune diseases, such as CIA and experimental autoimmune uveoretinitis (EAE) [19, 20] , in animal models and is therefore a potential target for anti-inflammatory treatment of human autoimmune diseases. However, our knowledge of the role of the CD200/CD200R1 axis in human diseases, especially in RA, is limited. This study demonstrated for the first time that there is aberrant expression of CD200/CD200R1 in cells from both the synovium and peripheral blood of RA patients. Th17 cells are pro-inflammatory CD4 + T cells characterized by the expression of RAR-related orphan receptor C (RORc) and the production of IL-17A (IL-17), IL-17F and IL-6, and they are thought to be the key effector cells in the pathogenesis of RA [21, 22] . Previous studies have demonstrated increased infiltration of Th17 cells and production of IL-17 in synovium from RA patients [23] , which not only up-regulated downstream proinflammatory cytokines, including TNF-a and IL-1b, but also synergized with these cytokines, leading to a vicious cycle of uncontrolled inflammation. There was also a study demonstrating that CD200 + chronic lymphocytic leukaemia cells suppressed production of the above mentioned pro-inflammatory cytokines and tumour cell lysis in mixed lymphocyte cultures [24] and that this suppression could be reversed by antagonistic CD200 antibodies. Furthermore, knockdown of CD200 in melanoma cells has been shown to enhance T cell responses in vitro. Of note, all the data were based on mixed lymphocyte cultures. It is therefore difficult to determine whether the reported effects are associated with direct inhibition or are transduced via antigen presenting cells (APCs). Our experiment with purified CD4 + T cells found that in vitro
CD200Fc could inhibit CD4 + T cell differentiation into Th17 cells in untreated RA patients. Moreover, the addition of CD200Fc also induced DOK2 phosphorylation in CD4 + T cells stimulated with anti-CD3/anti-CD28, which was consistent with a previous report [25] , and promoted CD4 + T cell apoptosis and necrosis in RA patients. In addition, CD200Fc down-regulated CCR6 expression and inhibited CCL20/CCR6-driven Th17 cell chemotaxis. These findings suggest that CD200 can engage CD200Fc could induce phosphorylation of DOK2 ( Fig. 2A) , thereby transducing an inhibitory signal on downstream phosphoinositide 3-kinase (PI3K) and extracellular signal-regulated kinase (ERK) pathways, which are pivotal in regulating cell proliferation and apoptosis and are overactivated in RA [13, 15, 21, 22] .
Monocytes/macrophages are well-described components of synovial membrane inflammation [26, 27] that are characterized by the production of cytokines that perpetuate inflammation and proteases that induce cartilage destruction in RA [2830] .
In our study we found that the abnormal CD200/ CD200R1 expression in RA had functional consequences for CD14 + monocytes. As CD200 lacks an intracellular signalling motif, it is presumed that CD200 exerts its immunological function via binding to its receptors. Peripheral CD14 + cells from RA patients cultured in the presence of CD200Fc had reduced osteoclastogenesis, and CD200Fc inhibited synovium and peripheral CD14 + cell-driven Th17 differentiation and down-regulated CD80 and CD86 expression on peripheral CD14 + cells challenged by LPS.
Synovium from RA patients had aberrant expression of CD200 and CD200R1. In contrast to synovium from OA patients (in whom CD200 + cells were mainly identified in the lining layer and, to a lesser extent, in the sublining layer where myeloid-derived cells are located), in synovium from RA patients, CD200 + cell infiltration extended beyond the lining and sublining layer into the deeper layer and adjacent lymphoid microstructures, where activated T and B cells are located. What is the underlying significance of such abnormal cell distribution in RA? Can such architectural disorganization with loss of contact inhibition of myeloidderived cells contribute to localized onset of inflammation in the joint? We found that in vitro addition of CD200Fc not only reduced osteoclastogenesis by peripheral CD14 + monocytes but also inhibited CD14 + monocyte-like synoviocyte (MLS)-driven Th17 differentiation, thereby maintaining T cell homeostasis by preventing the shift towards inflammation and consequently restraining structural damage. In addition, we found that CD200Fc also downregulated CD80 and CD86 expression by peripheral CD14 + cells, thereby inhibiting T cell activation and antigen presentation. These findings indicate that CD200/CD200R1 signalling can also exert immunosuppressive functions on myeloid-derived cells by inhibiting their differentiation into osteoclasts and MLS-driven Th17 differentiation as well as down-regulating co-stimulatory molecule expression. These functions restrain the strength of the autoreactive adaptive immune response and maintain the homeostasis involved in osteoimmunology. However, it remains to be explored whether the decreased peripheral CD200/ CD200R1 results from cell migration to the synovium in response to inflammation. Taken together, we demonstrated that there was abnormal expression of CD200 and CD200R1 in RA patients. This abnormal expression was corrected after treatment with a TNF-a antagonist plus MTX. Our functional analysis using in vitro CD200Fc collectively indicates that CD200/ CD200R1 exerts anti-inflammatory functions via multiple mechanisms and suggests a potential immunotherapeutic role for targeting CD200/CD200R1 in RA.
Rheumatology key messages
. CD200 and CD200R1 expression are abnormal in RA patients. . Aberrant expression of CD200/CD200R1 may contribute to abnormal Th17 cell differentiation, chemotaxis and osteoclastogenesis in RA patients.
